不同程度老年骨质疏松患者血清BALP、OPG/PYR比值变化及其与骨密度、骨折发生的相关性分析

摘要 目的：分析不同程度老年骨质疏松患者血清骨特异性碱性磷酸酶(BALP)、骨保护素(OPG)/吡啶啉(PYR)比值变化及其与骨密度、骨折发生的相关性。方法：选择我院自2020年11月至2023年7月接诊的70例老年骨质疏松患者作为观察组,其中轻-中度骨质疏松44例、重度骨质疏松26例;另选70例老年非骨质疏松者作为对照组。检测所有受试者血清BALP、OPG/PYR比值、腰椎、股骨颈和髋部的骨密度(BMD),分析BALP、OPG/PYR比值与不同骨骼部位BMD的关系,使用受试者工作特征(ROC)曲线分析BALP、OPG/PYR比值对老年骨质疏松骨折的预测效能。结果：观察组血清BALP水平高于对照组,OPG/PYR比值小于对照组（P＜0.05）;重度骨质疏松组血清BALP水平高于轻-中度骨质疏松组,OPG/PYR比值小于轻-中度骨质疏松组（P＜0.05）;观察组腰椎、股骨颈及髋部的BMD均小于对照组（P＜0.05）;经Pearson相关性分析,腰椎、股骨颈及髋部的BMD与血清BALP水平呈负相关（P＜0.05）,与OPG/PYR比值呈正相关（P＜0.05）;经ROC曲线分析,血清BALP联合OPG/PYR比值预测老年骨质疏松骨折的AUC为0.890。结论：老年骨质疏松患者血清BALP水平升高、OPG/PYR比值减小,与病情严重程度及骨密度有关,联合预测骨折的效能较好,值得进一步研究应用。     

益生菌补充剂治疗绝经后骨质疏松症或骨量减少的系统评价

目的 系统评价益生菌补充剂对绝经后骨质疏松症（PMOP）或骨量减少的有效性及安全性。方法 选取8个公共数据库,检索自建库至2022年9月,无语言限制,使用随机对照方法,评估补充益生菌补充剂对腰椎、股骨颈、总髋关节骨密度（BMD)、T值（T-value）、胶原降解产物（CTX）、I型前胶原氨基端前肽（PINP）、骨碱性磷酸酶（BALP）、骨钙素（BGP）水平和不良反应率的影响。结果 纳入了8篇RCT文献,647名参与者,治疗组有325名,对照组322名。结果显示益生菌组在提高PMOP和绝经后骨量减少患者的腰椎BMD、股骨颈BMD、T值、BGP和降低绝经后妇女CTX、BALP等方面显著优于对照组（P<0.05）。亚组分析结果显示益生菌治疗PMOP患者后显著提高腰椎BMD、股骨颈BMD、全髋关节BMD、T值和降低CTX、BALP优于对照组（P<0.05）。结论 益生菌干预PMOP和骨量减少患者后显著提高骨密度及降低骨代谢,对PMOP患者的作用更显著。     

血清miR-148a、miR-122-5p水平与骨质疏松症患者髋部骨折的关系及其预测价值分析

摘要 目的：研究血清微小核糖核酸-148a（miR-148a)、miR-122-5p水平与骨质疏松症患者髋部骨折的关系及其预测价值。方法：选取吉林大学第一医院从2019年1月～2021年1月收治的102例骨质疏松症患者作为研究对象。将其按照是否并发髋部骨折分为骨折组45例以及无骨折组57例,另选取健康体检志愿者40例作为对照组。比较三组血清miR-148a、miR-122-5p水平。采用单因素和多因素Logistic回归模型分析骨质疏松症患者髋部骨折的影响因素。采用受试者工作特征（ROC）曲线分析血清miR-148a、miR-122-5p水平预测骨质疏松症患者髋部骨折的效能。结果：骨折组血清miR-148a表达水平为（1.25±0.29）,相较于无骨折组的（1.04±0.24）以及对照组的（0.66±0.13）更高,且无骨折组miR-148a表达水平相较对照组更高;骨折组血清miR-122-5p表达水平为（0.60±0.06）,相较于无骨折组的（0.74±0.12）以及对照组的（1.01±0.17）更低,且无骨折组miR-122-5p表达水平相较对照组更低（均P＜0.05）。骨折组血清PINP、β-CTX水平及年龄、女性人数占比均高于无骨折组,骨密度评分低于无骨折组（均P＜0.05）。经多因素Logistic回归分析可得：年龄偏大、女性、骨密度评分降低、血清PINP、β-CTX、miR-148a水平升高均是骨质疏松症患者发生髋部骨折的危险因素,血清miR-122-5p水平升高是其保护因素（均P＜0.05）。经ROC曲线分析发现,血清miR-148a、miR-122-5p联合预测骨质疏松症患者发生髋部骨折的效能优于上述两项指标单独预测。结论：血清miR-148a水平升高以及血清miR-122-5p水平降低均可能增加骨质疏松症患者发生髋部骨折的风险,两指标联合检测具有辅助预测骨质疏松症患者发生髋部骨折风险的潜在价值。     

三维能量多普勒超声联合血清HE4、TK1、YKL-40对绝经后出血患者子宫内膜癌的预测价值

摘要 目的：研究三维能量多普勒超声联合血清人附睾蛋白4（HE4）、胸苷激酶1（TK1）、甲壳质酶蛋白40（YKL-40）对绝经后出血患者子宫内膜癌的预测价值。方法：选择我院2019年10月～2022年10月收治的150例绝经后出血患者。将其按照病理检查结果的差异分为子宫内膜癌组31例与子宫内膜良性增生组119例。对所有患者均开展三维能量多普勒超声检查,并检测血清HE4、TK1、YKL-40水平。以受试者工作特征曲线（ROC）分析三维能量多普勒超声联合血清HE4、TK1、YKL-40水平预测绝经后出血患者子宫内膜癌的效能。结果：子宫内膜癌组血流指数（FI）、血管形成指数（VI）、血管形成-血流指数（VFI）以及由该三参数构建的综合指数I相较于子宫内膜良性增生组均更高（均P＜0.05）。子宫内膜癌组血清HE4、TK1、YKL-40水平相较于子宫内膜良性增生组均更高（均P＜0.05）。经ROC曲线分析发现：三维能量多普勒超声联合血清HE4、TK1、YKL-40水平预测绝经后出血患者子宫内膜癌的曲线下面积（AUC）、灵敏度、特异度以及约登指数均高于上述四项单独预测。结论：三维能量多普勒超声联合血清HE4、TK1、YKL-40水平预测绝经后出血患者子宫内膜癌的效能较佳。     

骨愈灵片联合依降钙素注射液对骨质疏松症患者Oswestry功能障碍指数评分及骨密度、骨代谢指标的影响

摘要 目的：探讨骨愈灵片联合依降钙素注射液对骨质疏松症患者Oswestry功能障碍指数（ODI）评分及骨密度、骨代谢指标的影响。方法：选择我院2018年3月~2021年2月间收治的骨质疏松症患者156例,采用随机数字表法分为对照组（采用依降钙素注射液治疗）和研究组（采用骨愈灵片联合依降钙素注射液治疗）,各为78例。观察两组疗效、不良反应,对比两组ODI评分、腰椎L2-L4、桡骨远端1/3处和股骨颈的骨密度、骨代谢指标[血钙 、血磷 、骨钙素（BGP）和β-胶原降解产物（β-CTX）]、炎性指标[促生长因子（IGF-1）、白介素-1（IL-1）、白介素-8（IL-8）、肿瘤坏死因子-α（TNF-α）]水平。结果：研究组的临床总有效率明显高于对照组（P<0.05）。研究组治疗结束后ODI评分低于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。研究组治疗结束后腰椎L2-L4、桡骨远端1/3处、股骨颈骨密度均大于对照组（P<0.05）。研究组治疗结束后血钙、BGP水平高于对照组,血磷、β-CTX水平低于对照组（P<0.05）。研究组治疗结束后IGF-1水平高于对照组,IL-1、IL-8、TNF-α水平低于对照组（P<0.05）。结论：骨质疏松症患者采用依降钙素注射液联合骨愈灵片治疗,可改善骨代谢和骨密度,调节炎性因子水平,促进机体功能恢复,疗效明确。     

老年原发性骨质疏松症患者血清25-羟维生素D水平检测及与骨代谢指标的相关性分析

摘要 目的：检测并分析老年原发性骨质疏松症患者血清25-羟维生素D [25-(OH)D]水平及其与骨代谢指标的相关性。方法：选取2013年4月到2019年5月期间在我院接受治疗的老年原发性骨质疏松症患者166例作为骨质疏松组,另选取同期在我院进行体检的无骨质疏松老年人群117例作为无骨质疏松组。检测所有研究对象的血清25-(OH)D、I型胶原氨基酸延长肽（PINP）、β-胶原特殊序列（β-CTX）、N-端骨钙素（N-MID）的水平,并分析血清25-(OH)D与骨代谢指标的相关性。结果：166例老年原发性骨质疏松症患者的血清25-(OH)D水平为（16.82±4.52）ng/mL,其中维生素D缺乏64例、占38.56%,维生素D不足72例、占43.37%,维生素D正常30例,占18.07%。不同性别的老年原发性骨质疏松症患者的血清25-(OH)D水平比较差异无统计学意义（P>0.05）,不同性别的老年原发性骨质疏松症患者的维生素D缺乏、不足、正常占比比较差异无统计学意义（P>0.05）。骨质疏松组血清25-(OH)D水平明显低于无骨质疏松组（P<0.05）,骨质疏松组血清β-CTX水平明显高于无骨质疏松组（P<0.05）,骨质疏松组和无骨质疏松组的血清PINP、N-MID水平比较差异无统计学意义（P>0.05）。经Pearson相关分析显示,老年原发性骨质疏松症患者的血清25-(OH)D与β-CTX呈负相关（P<0.05）,与PINP、N-MID无明显的相关性（P>0.05）。结论：老年原发性骨质疏松症患者存在明显的维生素D缺乏、不足,但无明显的性别差异,血清25-(OH)D与β-CTX呈负相关,联合检测血清25-(OH)D和?茁-CTX有助于老年原发性骨质疏松症的早期诊断和治疗。     

血清脑钠肽、超敏C反应蛋白、可溶性ST2对阵发性心房颤动患者射频消融术后复发的预测价值研究

摘要 目的：探讨血清脑钠肽（BNP）、超敏C反应蛋白（hs-CRP）、可溶性致瘤抑制素2（sST2）对阵发性心房颤动（AF）患者射频消融（RFA）术后复发的预测价值。方法：选择2016年1月至2020年12月我院收治的接受RFA术治疗的82例阵发性AF患者,术后随访12个月,根据术后是否复发分为复发组（25例）和未复发组（57例）。检测患者血清BNP、hs-CRP、sST2水平,收集临床相关资料,采用多因素Logistic回归模型分析影响阵发性AF患者RFA术后复发的因素,采用受试者工作特征（ROC）曲线分析血清BNP、hs-CRP、sST2预测阵发性AF患者RFA术后复发的价值。结果：复发组血清BNP、hs-CRP、sST2水平高于未复发组（P＜0.05）。血清BNP、hs-CRP、sST2水平升高、AF病程增长是影响阵发性AF患者RFA术后复发的危险因素（P＜0.05）。血清BNP、hs-CRP、sST2预测阵发性AF患者消融术后复发的曲线下面积分别为0.720、0.694、0.718,联合三者预测阵发性AF患者RFA术后复发的曲线下面积为0.866,高于BNP、hs-CRP、sST2单独预测。结论：阵发性AF患者血清BNP、hs-CRP、sST2水平升高是RFA术后复发的危险因素,联合检测血清BNP、hs-CRP、sST2水平有助于预测阵发性AF患者RFA术后复发。     

老年腰椎间盘突出症患者术后下肢深静脉血栓形成的影响因素及术前D-D、TM、Leptin联合应用的预测价值

摘要 目的：分析老年腰椎间盘突出症（LDH）患者术后下肢深静脉血栓形成（LDVT）的影响因素并探讨术前D-二聚体（D-D）、血栓调节蛋白（TM）、瘦素（Leptin）联合应用的预测价值。方法：选取2020年1月～2021年12月广州医科大学附属第三医院收治的412例接受腰椎椎间融合术（LIF）老年LDH患者,根据术后是否发生LDVT将其分为LDVT组和非LDVT组。收集老年LDH患者临床资料,采用酶联免疫吸附法检测术前血清D-D、TM、Leptin水平。采用多因素Logistic回归分析老年LDH患者LIF术后LDVT的影响因素,采用受试者工作特征（ROC）曲线分析术前血清D-D、TM、Leptin水平对老年LDH患者LIF术后LDVT的预测价值。结果：412例老年LDH患者LIF术后LDVT发生率为21.12%（87/412）。多因素Logistic回归分析显示,年龄增加、体质指数≥24 kg/m²、卧床时间≥7 d、D-D升高、TM升高、Leptin升高为老年LDH患者LIF术后LDVT的独立危险因素（P＜0.05）。ROC曲线分析显示,术前血清D-D、TM、Leptin水平单独与联合预测老年LDH患者LIF术后LDVT的曲线下面积分别为0.766、0.760、0.767、0.894,联合预测的曲线下面积大于D-D、TM、Leptin单独预测。结论：老年LDH患者LIF术后LDVT发生与年龄、体质指数、卧床时间和D-D、TM、Leptin有关,术前血清D-D、TM、Leptin水平联合预测老年LDH患者LIF术后LDVT的价值较高。     

血清miR-203a、miR-31-5p、miR-19b-1-5p水平与股骨颈骨折患者骨折延迟愈合的关系及其预测价值分析

摘要 目的：探讨血清微小核糖核酸（miR）-203a、miR-31-5p、miR-19b-1-5p水平与股骨颈骨折患者术后骨折延迟愈合的关系及对术后骨折延迟愈合的预测价值。方法：选择2020年1月~2022年10月在徐州医科大学附属医院行内固定治疗的292例新鲜股骨颈骨折患者为研究对象。于术后4周复查时,检测患者血清miR-203a、miR-31-5p、miR-19b-1-5p水平;并根据其骨折愈合情况分为延迟组（n=36）和愈合组（n=256）。采用多因素Logistic回归分析股骨颈骨折患者术后骨折延迟愈合的影响因素。采用受试者工作特征（ROC）曲线分析血清miR-203a、miR-31-5p、miR-19b-1-5p对股骨颈骨折患者术后骨折延迟愈合的预测价值。结果：术后4个月复查时,骨折延迟愈合发生率为12.33%。两组年龄、吸烟史、合并糖尿病组间比较,差异有统计学意义（P＜0.05）。愈合组血清miR-203a、miR-31-5p、miR-19b-1-5p水平均高于延迟组（P<0.05）。多因素Logistic回归分析结果显示,年龄≥60岁、合并糖尿病、血清miR-203a、miR-31-5p、miR-19b-1-5p水平降低是股骨颈骨折患者术后骨折延迟愈合的独立危险因素（P＜0.05）。ROC曲线结果显示,三者联合检测的曲线下面积（AUC）（0.95CI）为0.841（0.738~0.936）,高于各指标单独应用时的AUC,三者联合检测的灵敏度和特异度亦高于单一指标检测。结论：血清miR-203a、miR-31-5p、miR-19b-1-5p在股骨颈骨折术后骨折延迟愈合患者中呈低表达,是骨折延迟愈合的独立危险因素,三者联合检测对股骨颈骨折患者骨折延迟愈合具有较高的预测价值。     

血清PTH及肿瘤标志物在类风湿关节炎患者合并骨质疏松症诊断价值分析

摘要 目的：研究血清甲状旁腺激素（PTH）和肿瘤标志物对类风湿性关节炎合并骨质疏松症（RAOP）的诊断价值。方法：选取2019年1月-2021年12月在我院就诊的60例RAOP患者为研究对象,并选取同期在我院就诊的类风湿性关节炎（RA）患者作为对照。比较两组患者血清PTH、甲胎蛋白（AFP）、癌胚抗原（CEA）、癌抗原125（CA125）、癌抗原199（CA199）和癌抗原724（CA724）。通过pearsonr相关系数分析各指标的相关性,通过Logistic回归分析RAOP的影响因素和通过受试者工作特征（ROC）曲线分析各指标对RAOP的诊断价值。结果：（1）RAOP患者血清PTH、CA125和CA199水平均显著高于RA患者（P<0.05）,而血清CA724水平显著低于RA患者（P<0.05）,并且血清AFP和CEA水平与RA患者比较无差异（P>0.05）;（2）RAOP患者血清PTH与血清PTH水平与血清CA125和CA199水平呈正相关（P<0.05）,与血清CA724水平呈负相关（P<0.05）,与血清AFP和CEA水平不相关（P>0.05）;（3）Logistic回归分析显示：血清PTH、CA125、CA199、CA724是影响类风湿性关节炎合并骨质疏松症的独立影响因素（P<0.05）;（4）ROC曲线分析显示：血清PTH、CA125、CA199对RAOP具有诊断价值,诊断敏感性和特异性分别为90.00%和86.97%、80.36 %和78.97 %、75.62 %和75.12 %。结论：血清PTH、CA125和CA199在RAOP患者含量升高,是影响RAOP的独立危险因素,可作为诊断RAOP的指标。     

Prevalence of Osteoporosis in Ambulatory Postmenopausal Women from A Semiurban Region in Southern India: Relationship to Calcium Nutrition and Vitamin D Status

ObjectiveTo assess the prevalence of osteoporosis in healthy ambulatory postmenopausal Indian women as measured by dual-energy x-ray absorptiometry and to study the dietary calcium intake and vitamin D status and their influence on bone mineral density (BMD).MethodsWe conducted a community-based crosssectional study in a semiurban region. A randomized cluster sampling technique was used. The study cohort consisted of 150 ambulatory postmenopausal women (≥ 50 years old). Dual-energy x-ray absorptiometry for BMD was performed at the lumbar spine and femoral neck. Dietary calcium intake and biochemical variables were assessed.ResultsThe prevalence of osteoporosis was 48% at the lumbar spine, 16.7% at the femoral neck, and 50% at any site. The mean dietary calcium intake was much lower than the recommended intake for this age-group. There was a significant positive correlation between body mass index and BMD at the lumbar spine and the femoral neck (r = 0.4; P = .0001). BMD at the femoral neck was significantly less (mean, 0.657 versus 0.694 g/cm²) in the vitamin D-insufficient study subjects in comparison with the vitamin D-sufficient women (P = .03).ConclusionThe high prevalence of osteoporosis and vitamin D insufficiency in this semiurban group of postmenopausal women in India is a major health concern. Measures such as adequate calcium intake and vitamin D supplementation in women of this age-group may be beneficial. (Endocr Pract. 2008;14:665-671)     

Effect of cervus and cucumis polypeptide combined with zoledronic acid on bone metabolic biochemical markers in glucocorticoids – Induced osteoporosis patients

ObjectiveTo investigate the effect of cervus and cucumis polypeptide combined with zoledronic acid on bone metabolic biochemical markers in glucocorticoids - induced osteoporosis patients.MethodsA total of 100 patients with glucocorticoids - induced osteoporosis admitted to our hospital from January 2015 to June 2017 were enrolled in this study. Patients were divided into observation group and control group by random number table method, 50 cases in each group. Patients in the observation group were treated with deer melon polypeptide in combination with zoledronic acid, and patients in the control group were treated with zoledronic acid alone. The patients in both groups were treated for 2 months. The changes of bone mineral density (BMD) and biochemical markers of bone metabolism in lumbar vertebrae L1-4, left femoral neck and large trochanter were analyzed before and after treatment.ResultsThe pre- BMD at lumbar spine L_1-4, left femoral neck and great trochanter had no statistic difference (P > 0.05), the BMD at each sites improved after treatment, and the difference were statistical before and after treatment (P < 0.05). BMD at above sites of two groups after treatment had statistical difference (P < 0.05), and the BMD at lumbar spine L_1-4, left femoral neck and great trochanter in the observation group was higher than that of the control group. There were no significant differences in PTH, 25-(OH)D3, TRACP, β-CTX and BGP levels between the two groups before treatment (P > 0.05). The levels of 25-(OH)D3, TRACP, β-CTX and BGP in the two groups were significantly improved after treatment (P < 0.05), and the levels of PTH, TRACP and β-CTX in the observation group were significantly lower than those in the control group. The levels of 25-(OH) D3 and BGP were significantly higher than those of the control group (P < 0.05).ConclusionThe cervus and cucumis polypeptide combined with zoledronic acid can improve the BMD at lumbar spine L_1-4, left femoral neck and great trochanter, and ameliorate the bone metabolic biochemical markers for patients with glucocorticoids - induced osteoporosis.     

右归丸与液体钙片对老年骨质疏松症患者血清雌激素和骨钙素水平的影响

目的:研究右归丸联合液体钙片对老年骨质疏松症患者血清雌激素水平、骨钙素(BGP)水平及临床疗效的影响。方法:选取2014年10月至2015年9月本院收治的82例老年骨质疏松症患者,根据入院顺序分为观察组和对照组,每组41例。对照组使用骨化三醇软胶囊和液体钙软胶囊进行治疗,观察组在此基础上加以右归丸进行治疗。比较两组患者治疗前和治疗1个月后血清雌二醇(E2)水平、BGP水平、骨密度变化,分析两组患者的临床疗效。结果:治疗后,观察组的血清E2水平显著高于对照组(P0.05),BGP水平显著低于对照组(P0.05),腰椎L1-4正位、右侧股骨颈、左侧股骨颈骨密度显著高于对照组(p0.05),总临床疗效率显著高于对照组(P0.05)。结论:右归丸联合液体钙片治疗老年骨质疏松症患者能明显改善患者血清雌激素、BGP水平,增加骨密度,临床疗效良好。     

Vitamin d status and its relationship with bone mineral density and parathyroid hormone in southeast asian adults with low bone density

ObjectiveTo investigate the vitamin D sufficiency status and the relationships among serum 25-hydroxyvitamin D [25(OH)D] levels, intact parathyroid hormone (iPTH) levels, and bone mineral density (BMD) in patients attending an osteoporosis clinic in Singapore.MethodsIn total, 193 adults with or without prevalent fragility fractures and with low BMD at the femoral neck, total hip, or lumbar spine underwent assessment. Multivariate regression models were used to investigate the relationships among serum 25(OH)D, iPTH, and BMD.ResultsThe mean values (standard deviation) for age of the patients and serum 25(OH)D level were 61 (14) years and 26.05 (7.97) ng/mL, respectively. In 72% of patients, serum 25(OH)D levels were below 30 ng/mL. There was no association between 25(OH)D levels and BMD at the femoral neck, total hip, or lumbar spine(P = .568, .461, and .312, respectively). Serum iPTH levels were negatively associated with BMD at the total hip(P = .035) and the lumbar spine (P = .019). At levels < 30 ng/mL, 25(OH)D was negatively associated with iPTH (P = .036).ConclusionAmong this Southeast Asian population of patients with low BMD, no direct relationship between serum 25(OH)D levels and BMD was observed. A negative correlation existed, however, between iPTH and 25(OH)D at serum 25(OH)D concentrations < 30 ng/mL, and serum iPTH levels showed a significant negative association with BMD at the total hip and lumbar spine. These significant negative associations between iPTH levels and BMD at the total hip and lumbar spine underscore the critical role of this hormone in bone metabolism and health. (Endocr Pract. 2011;17:226-234)     

Long-Term Follow-up of patients on Drug Holiday from Bisphosphonates: Real-World Setting

ObjectiveAtypical femoral fractures and osteoporosis of the jaw have been associated with prolonged bisphosphonate therapy for postmenopausal osteoporosis. American Association of Clinical Endocrinologists guidelines suggest a drug holiday after 4 to 5 years of bisphosphonate treatment for moderate-risk patients and 10 years for high-risk patients, but there are minimal data on safe holiday durations. A recent U.S. Food and Drug Administration perspective suggests a treatment duration of 3 to 5 years. Our aim was to describe a group of patients on drug holiday and identify fracture risk.MethodsA retrospective chart review was conducted of 209 patients who started a bisphosphonate drug holiday between 2005 and 2010. Collected data included bone mineral density (BMD), markers of bone turnover, vitamin D status, and clinical and radiographic reports of fractures.ResultsEleven of 209 patients (5.2%) developed a fracture. Their mean age was 69.36 years (±15.58), and the mean lumbar spine and femoral neck T-scores were −2.225 (±1.779) and −2.137 (±0.950), respectively. All patients had a significant increase in bone-specific alkaline phosphatase at 6 months, which was more pronounced in the fracture group (3.0 ± 0.6083 μg/L vs. 1.16 ± 1.9267 μg/L). Over 4 years, there was no significant change in mean lumbar spine BMD for the entire cohort, but there was a statistically significant decline in the femoral neck BMD at year 2 (−0.0084 ± 0.03 gm/cm²).ConclusionThe current practice of initiating BP holidays needs further evaluation, particularly in the real-world setting. Elderly patients and those with very low BMD warrant close follow-up during a drug holiday. A fracture, early significant rise in bone turnover markers, and/or a decline in BMD should warrant resumption of osteoporosis therapy. (Endocr Pract. 2013;19:989-994)     

Increased Bone Mineral Density in Male Patients With Idiopathic Hypogonadotropic Hypogonadism Who Undergo Sex Hormone Therapy: Findings From Cross-Sectional and Longitudinal Studies

ObjectiveThis retrospective observational study assessed the long-term impact of pulsatile gonadotropin-releasing hormone, combined gonadotropin, or testosterone replacement therapy on total hip, femoral, and lumbar bone mineral density (BMD) and Z-scores in adult men with idiopathic hypogonadotropic hypogonadism (IHH).MethodsIn the cross-sectional study, 69 patients were allocated to untreated (n = 42) and treated (n = 27) groups. The untreated group included IHH patients without hormone therapy history, while the treated group included age- and body mass index-matched patients who had received hormone therapy for at least 5 years. The longitudinal study included 53 IHH patients, and their hip and lumbar BMDs were measured several times during hormone therapy. We then evaluated the changes in their BMD.ResultsOur cross-sectional study showed that the treated group had a significantly higher BMD and Z-score for total hip, femoral neck, and lumbar spine (P < 0.001 for all) than the untreated group, and the average bone mass even reached the age-matched normal range. The prevalence of low BMD was 80.95% and 11.11% in untreated and treated groups, respectively. In the longitudinal study (N = 53), the total hip, femoral neck, and lumbar spine BMD gradually increased during treatment. The lumbar spine showed a greater increment in BMD compared with the total hip and femoral neck (P < 0.05).ConclusionSex hormone therapy improved hip and lumbar spine BMD and Z-scores in patients with IHH. The lumbar spine showed a greater improvement in BMD compared with the total hip and femoral neck.     

Correlation Between Bone Markers and Bone Mineral Density in Postmenopausal Women with Osteoporosis

ObjectiveTo study the relationship between bone markers and bone mineral density (BMD) in an effort to identify their utility in postmenopausal women with osteoporosis.MethodsEighty-two consecutive postmenopausal women with untreated osteoporosis were included in the study. Forearm, spinal, and femoral BMD by dual-energy x-ray absorptiometry and markers of bone formation (serum osteocalcin and bone-specific alkaline phosphatase) and bone resorption (urinary free deoxypyridinoline) were measured in all patients. Patients with low serum vitamin D levels, secondary osteoporosis, or clinically significant systemic disease were excluded from the study. The patients were classified on the basis of BMD of the lumbar spine into the following 3 groups: mild (n = 23) (T score -2.5 through -3), moderate (n = 42) (T score -3.1 through -4), or severe (n = 17) (T score ≤-4.1) osteoporosis. One-way analysis of variance and Pearson correlation were used for statistical analysis, with a P value < .05 being considered significant.ResultsSerum osteocalcin was significantly different among the 3 study groups (4.1 ± 2.7, 4.5 ± 3.1, and 6.7 ± 5.6 ng/mL, respectively; P = .0349) and had a significant negative correlation with BMD (r² = -0.0779; P = .0168). Other bone markers such as bone-specific alkaline phosphatase and urinary free deoxypyridinoline did not correlate with the underlying BMD.ConclusionIn our study, osteocalcin was significantly correlated with BMD in postmenopausal women with osteoporosis. Other bone markers did not correlate with BMD. Further large-scale population data and analyses are needed to confirm these findings. (Endocr Pract. 2008;14:1102-1107)     

Association between Levels of Serum Ferritin and Bone Mineral Density in Korean Premenopausal and Postmenopausal Women: KNHANES 2008–2010

Background

As women go through menopause, serum estrogen decreases and ferritin increases. Decreased serum estrogen is well known to cause detrimental effects on bone health; however, data on the associations of serum ferritin with BMD before and after menopause are still lacking. Therefore, this study aimed to investigate the association between serum ferritin levels and BMD in premenopausal and postmenopausal Korean women.

Methods

This study was performed using data from the 2008–2010 Korean National Health and Nutrition Examination Survey, including 7300 women (4229 premenopausal and 3071 postmenopausal). BMD was measured using dual X-ray absorptiometry at the femur and the lumbar spine, and serum ferritin levels were measured by chemiluminescent immunoassay.

Results

Median serum ferritin levels in postmenopausal women were higher than those in premenopausal women despite the same age ranges. Serum ferritin levels were only significantly correlated with BMD on the lumbar spine (β = −0.189, p-value = 0.005) in premenopausal women after adjusting confounding factors. Additionally, BMD on the lumbar spine had tended to decrease as serum ferritin quartiles increase (P for trend = 0.035) in premenopausal women after adjusting confounding factors. On the other hand, there were no significant associations between serum ferritin levels and BMD on the total femur and, femur neck in premenopausal women, and BMD on the total femur, femur neck, and lumbar spine in postmenopausal women.

Conclusion

Increased serum ferritin levels were significantly associated with BMD in premenopausal women, particularly on the lumbar spine, but not in postmenopausal women.     

Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis

ObjectiveTo compare bone mineral density (BMD) changes after 12 months of treatment with denosumab or bisphosphonates in postmenopausal women with severe osteoporosis after stopping teriparatide therapy.MethodsWe retrospectively analyzed 140 postmenopausal women (mean age, 74.2 years) with severe osteoporosis who had been treated with teriparatide for 18 to 24 months at our outpatient clinic in a tertiary endocrine center between 2006 and 2015. After stopping teriparatide therapy, they continued treatment with a bisphosphonate (alendronate, risedronate, ibandronate, or zoledronic acid) or denosumab while receiving daily vitamin D and calcium. BMD at the lumbar spine (LS), total hip (TH), and femoral neck (FN) was measured by dual energy x-ray absorptiometry when teriparatide therapy was discontinued (baseline) and after 12 months of further treatment. Multivariate linear regression models were used to identify the predictors of BMD gain.ResultsAfter stopping teriparatide therapy, 70 women continued treatment with bisphosphonates and 70 received denosumab. LS, but not TH or FN, BMD gain was significantly greater in the denosumab group than in the bisphosphonates group at 12 months. Multivariate analysis showed that BMD gain at the LS was negatively associated with bisphosphonate versus denosumab treatment and positively associated with baseline serum total procollagen type I N-terminal propeptide. BMD gains at the FN were predicted by higher baseline serum urate levels. BMD gains at the TH and FN were negatively associated with pretreatment BMD gains at the same site.ConclusionTwelve months after stopping teriparatide therapy, sequential denosumab treatment appeared to yield higher additional LS BMD gain on average compared with bisphosphonates treatment.